In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections

Documenti analoghi

• In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens
  di: Stone, Gregory G., et al.
  Pubblicazione: (2017)
• In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial
  di: Stone, Gregory G., et al.
  Pubblicazione: (2020)
• Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets
  di: Mendes, Rodrigo E., et al.
  Pubblicazione: (2017)
• Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia
  di: Das, Shampa, et al.
  Pubblicazione: (2019)
• Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
  di: Goodlet, Kellie J, et al.
  Pubblicazione: (2016)